EMADrug Approval
European Medicines Agency Approves Pembrolizumab in Triple-Negative Breast Cancer
EMA·Friday, February 28, 2025·Global
The EMA approved pembrolizumab (Keytruda) in combination with chemotherapy for locally recurrent unresectable or metastatic triple-negative breast cancer.
Related Conditions
Share this article
Help others stay informed